1. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, Du Beshter B, Adelson MD, Hoskins WJ (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamid versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955
2. Arian-Schad KS, Kapp DS, Hackl A, Juettner FM, Leitner H, Porsch G, Lahou-sen M, Pickel H (1990) Radiation therapy in stage III ovarian cancer following surgery and chemotherapy. Prognostic factors, patterns of relapse, and toxicity: A preliminary report Gynecol Oncol 39:47–55
3. Barakat RR, Rubin SC, Wong G, Saigo PE, Markman M, Hoskins WJ (1992) Mixed mesodermal tumor of the ovary: Analsis of prognostic factors in 31 cases. Obstet Gynecol 80:660–664
4. Berek JS (1992) Second-look versus-second-nature. Gynecol Oncol 44:1 – 2
5. Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Ziegelboim J (1991) A phase I-II trial of intraperitoneal cisplatin and alfa-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40:237–243